Symbols / NRSN
NRSN Chart
About
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 27.12M |
| Enterprise Value | 19.48M | Income | -8.66M | Sales | — |
| Book/sh | -0.02 | Cash/sh | 0.03 | Dividend Yield | — |
| Payout | 0.00% | Employees | 17 | IPO | — |
| P/E | — | Forward P/E | -4.55 | PEG | — |
| P/S | — | P/B | -39.00 | P/C | — |
| EV/EBITDA | -2.28 | EV/Sales | — | Quick Ratio | 0.69 |
| Current Ratio | 0.71 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.36 | EPS next Y | -0.18 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-04-07 16:00 | ROA | -3.04% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 29.70M |
| Shs Float | 16.50M | Short Float | 1.94% | Short Ratio | 2.03 |
| Short Interest | — | 52W High | 2.60 | 52W Low | 0.68 |
| Beta | 1.61 | Avg Volume | 306.56K | Volume | 208.38K |
| Target Price | $10.17 | Recom | Strong_buy | Prev Close | $0.88 |
| Price | $0.82 | Change | -6.93% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.17
Mean price target
2. Current target
$0.82
Latest analyst target
3. DCF / Fair value
$-3.98
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.82
Low
$7.50
High
$14.00
Mean
$10.17
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-22 | main | D. Boral Capital | Buy → Buy | $14 |
| 2025-11-24 | main | D. Boral Capital | Buy → Buy | $14 |
| 2025-08-15 | main | D. Boral Capital | Buy → Buy | $14 |
| 2025-07-10 | main | D. Boral Capital | Buy → Buy | $14 |
| 2025-05-12 | init | D. Boral Capital | — → Buy | $14 |
| 2024-12-16 | down | Maxim Group | Buy → Hold | — |
- New Alzheimer’s treatment from NeuroSense gets U.S. patent through 2043 - Stock Titan Wed, 21 Jan 2026 08
- New Analyst Forecast: $NRSN Given $14.0 Price Target - Quiver Quantitative Mon, 24 Nov 2025 08
- Neurosense Therapeutics stock rises after securing Australian patent for PrimeC - Investing.com Mon, 09 Feb 2026 08
- NeuroSense Provides Business Update and Progress for the First Half of 2025 - PR Newswire Fri, 01 Aug 2025 07
- ALS trial: NeuroSense drug extends survival by 14 months, cuts deaths 65% - Stock Titan Wed, 18 Feb 2026 14
- NeuroSense Therapeutics Calls March 10, 2026 Special Meeting to Approve Share Capital Increase - TipRanks Fri, 13 Feb 2026 08
- Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights - Yahoo Finance Mon, 12 May 2025 07
- $NRSN Q3 2025 Earnings Preview: Recent $NRSN Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative ue, 16 Dec 2025 08
- NeuroSense (NASDAQ: NRSN) plans April 2026 Health Canada pre-NDS as it eyes mid-2026 NDS - Stock Titan hu, 04 Dec 2025 08
- Why is NRSN stock going down - GDP Growth & Weekly Return Optimization Plans - mfd.ru Sun, 15 Feb 2026 01
- NeuroSense Wins Australian Patent to Extend PrimeC IP Protection Through 2042 - TipRanks Mon, 09 Feb 2026 08
- Australian patent extends protection for ALS, Alzheimer’s drug PrimeC to 2042 - Stock Titan Mon, 09 Feb 2026 08
- NRSN Stock Price and Chart — NASDAQ:NRSN - TradingView Fri, 10 Dec 2021 08
- NeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve Cash - TipRanks ue, 06 Jan 2026 08
- NeuroSense (Nasdaq: NRSN) to start pivotal Phase 3 PARAGON trial of PrimeC in ALS - Stock Titan Mon, 24 Nov 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -9.88M | -14.24M | -10.52M | -6.74M |
| TotalUnusualItems | 1.00K | 2.21M | -22.00K | 2.70M |
| TotalUnusualItemsExcludingGoodwill | 1.00K | 2.21M | -22.00K | 2.70M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -10.21M | -10.11M | -10.49M | -4.04M |
| ReconciledDepreciation | 22.00K | 21.00K | 12.00K | 3.00K |
| EBITDA | -9.88M | -12.03M | -10.54M | -4.04M |
| EBIT | -9.90M | -12.05M | -10.55M | -4.04M |
| NetInterestIncome | -309.00K | -270.00K | 84.00K | -1.15M |
| InterestExpense | 11.00K | 15.00K | 0.00 | |
| InterestIncome | 2.00K | 178.00K | 91.00K | 0.00 |
| NormalizedIncome | -10.21M | -12.32M | -10.47M | -6.74M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -10.21M | -10.11M | -10.49M | -4.04M |
| TotalExpenses | 9.90M | 12.05M | 10.55M | 5.59M |
| TotalOperatingIncomeAsReported | -9.90M | -12.05M | -10.55M | -5.59M |
| DilutedAverageShares | 18.91M | 13.64M | 11.50M | 6.24M |
| BasicAverageShares | 18.91M | 13.64M | 11.50M | 6.24M |
| DilutedEPS | -0.54 | -0.74 | -0.91 | -0.65 |
| BasicEPS | -0.54 | -0.74 | -0.91 | -0.65 |
| DilutedNIAvailtoComStockholders | -10.21M | -10.11M | -10.49M | -4.04M |
| NetIncomeCommonStockholders | -10.21M | -10.11M | -10.49M | -4.04M |
| NetIncome | -10.21M | -10.11M | -10.49M | -4.04M |
| NetIncomeIncludingNoncontrollingInterests | -10.21M | -10.11M | -10.49M | -4.04M |
| NetIncomeContinuousOperations | -10.21M | -10.11M | -10.49M | -4.04M |
| PretaxIncome | -10.21M | -10.11M | -10.49M | -4.04M |
| OtherIncomeExpense | 1.00K | 2.21M | -22.00K | 2.70M |
| GainOnSaleOfSecurity | 1.00K | 2.21M | -22.00K | 2.70M |
| NetNonOperatingInterestIncomeExpense | -309.00K | -270.00K | 84.00K | -1.15M |
| TotalOtherFinanceCost | 311.00K | 448.00K | 7.00K | 1.15M |
| InterestExpenseNonOperating | 11.00K | 15.00K | 0.00 | |
| InterestIncomeNonOperating | 2.00K | 178.00K | 91.00K | 0.00 |
| OperatingIncome | -9.90M | -12.05M | -10.55M | -5.59M |
| OperatingExpense | 9.90M | 12.05M | 10.55M | 5.59M |
| ResearchAndDevelopment | 5.70M | 7.27M | 5.59M | 3.08M |
| SellingGeneralAndAdministration | 4.20M | 4.78M | 4.97M | 2.50M |
| GeneralAndAdministrativeExpense | 4.20M | 4.78M | 4.97M | 2.50M |
| OtherGandA | 2.67M | 2.29M | 1.62M | 514.00K |
| InsuranceAndClaims | 309.00K | 511.00K | 1.17M | 68.00K |
| SalariesAndWages | 1.23M | 1.97M | 2.17M | 1.92M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 23.23M | 15.38M | 11.78M | 10.94M |
| ShareIssued | 23.23M | 15.38M | 11.78M | 10.94M |
| TotalDebt | 73.00K | 142.00K | 211.00K | 0.00 |
| TangibleBookValue | 2.58M | -1.76M | 5.62M | 9.01M |
| InvestedCapital | 2.58M | -1.76M | 5.62M | 9.01M |
| WorkingCapital | 2.41M | -543.00K | 5.66M | 10.81M |
| NetTangibleAssets | 2.58M | -1.76M | 5.62M | 9.01M |
| CapitalLeaseObligations | 73.00K | 142.00K | 211.00K | 0.00 |
| CommonStockEquity | 2.58M | -1.76M | 5.62M | 9.01M |
| TotalCapitalization | 2.58M | -1.76M | 5.62M | 9.01M |
| TotalEquityGrossMinorityInterest | 2.58M | -1.76M | 5.62M | 9.01M |
| StockholdersEquity | 2.58M | -1.76M | 5.62M | 9.01M |
| RetainedEarnings | -36.66M | -26.12M | -20.79M | -8.45M |
| AdditionalPaidInCapital | 39.24M | 24.36M | 26.41M | 17.45M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.99M | 4.94M | 2.09M | 2.42M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 1.49M | 365.00K | 1.83M |
| DerivativeProductLiabilities | 0.00 | 1.41M | 218.00K | 1.83M |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 73.00K | 147.00K | 0.00 |
| LongTermCapitalLeaseObligation | 0.00 | 73.00K | 147.00K | 0.00 |
| CurrentLiabilities | 1.99M | 3.46M | 1.73M | 597.00K |
| CurrentDebtAndCapitalLeaseObligation | 73.00K | 69.00K | 64.00K | |
| CurrentCapitalLeaseObligation | 73.00K | 69.00K | 64.00K | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 209.00K | 370.00K | ||
| PayablesAndAccruedExpenses | 1.92M | 3.39M | 1.29M | 597.00K |
| CurrentAccruedExpenses | 759.00K | 1.93M | 794.00K | 558.00K |
| Payables | 1.16M | 1.46M | 498.00K | 39.00K |
| AccountsPayable | 1.16M | 1.46M | 498.00K | 39.00K |
| TotalAssets | 4.58M | 3.19M | 7.71M | 11.43M |
| TotalNonCurrentAssets | 173.00K | 269.00K | 329.00K | 19.00K |
| OtherNonCurrentAssets | 23.00K | 22.00K | 23.00K | |
| NetPPE | 150.00K | 247.00K | 306.00K | 19.00K |
| AccumulatedDepreciation | -60.00K | -38.00K | -17.00K | -5.00K |
| GrossPPE | 210.00K | 285.00K | 323.00K | 24.00K |
| Leases | 3.00K | 3.00K | 3.00K | 0.00 |
| OtherProperties | 229.00K | |||
| MachineryFurnitureEquipment | 123.00K | 120.00K | 91.00K | 24.00K |
| BuildingsAndImprovements | 84.00K | 162.00K | 229.00K | 0.00 |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 4.40M | 2.92M | 7.38M | 11.41M |
| RestrictedCash | 35.00K | 40.00K | 36.00K | 39.00K |
| PrepaidAssets | 825.00K | 70.00K | 124.00K | 132.00K |
| Receivables | 164.00K | 166.00K | 131.00K | 178.00K |
| OtherReceivables | 164.00K | 166.00K | 131.00K | 178.00K |
| CashCashEquivalentsAndShortTermInvestments | 3.38M | 2.64M | 7.09M | 11.06M |
| OtherShortTermInvestments | 0.00 | 3.55M | 0.00 | |
| CashAndCashEquivalents | 3.38M | 2.64M | 3.54M | 11.06M |
| CashFinancial | 11.06M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -10.14M | -8.38M | -7.69M | -1.56M |
| RepaymentOfDebt | -80.00K | -79.00K | 0.00 | |
| IssuanceOfCapitalStock | 11.30M | 4.33M | 0.00 | 9.86M |
| CapitalExpenditure | -3.00K | -29.00K | -70.00K | -17.00K |
| EndCashPosition | 3.38M | 2.64M | 3.54M | 11.06M |
| BeginningCashPosition | 2.64M | 3.54M | 11.06M | 699.00K |
| EffectOfExchangeRateChanges | -41.00K | 8.00K | -88.00K | 18.00K |
| ChangesInCash | 779.00K | -911.00K | -7.43M | 10.35M |
| FinancingCashFlow | 10.91M | 3.98M | 3.77M | 11.90M |
| CashFlowFromContinuingFinancingActivities | 10.91M | 3.98M | 3.77M | 11.90M |
| NetOtherFinancingCharges | -391.00K | -364.00K | 800.00K | |
| ProceedsFromStockOptionExercised | 0.00 | 5.00K | 3.77M | 1.24M |
| NetCommonStockIssuance | 11.30M | 4.33M | 0.00 | 9.86M |
| CommonStockIssuance | 11.30M | 4.33M | 0.00 | 9.86M |
| NetIssuancePaymentsOfDebt | -80.00K | -79.00K | 0.00 | |
| NetLongTermDebtIssuance | -80.00K | -79.00K | 0.00 | |
| LongTermDebtPayments | -80.00K | -79.00K | 0.00 | |
| InvestingCashFlow | 1.00K | 3.47M | -3.59M | -17.00K |
| CashFlowFromContinuingInvestingActivities | 1.00K | 3.47M | -3.59M | -17.00K |
| NetOtherInvestingChanges | 4.00K | -3.00K | -20.00K | |
| InterestReceivedCFI | 178.00K | 49.00K | 0.00 | |
| NetInvestmentPurchaseAndSale | 0.00 | 3.50M | -3.50M | 0.00 |
| PurchaseOfInvestment | -3.50M | 0.00 | ||
| NetPPEPurchaseAndSale | -3.00K | -29.00K | -70.00K | -17.00K |
| PurchaseOfPPE | -3.00K | -29.00K | -70.00K | -17.00K |
| OperatingCashFlow | -10.13M | -8.35M | -7.62M | -1.54M |
| CashFlowFromContinuingOperatingActivities | -10.13M | -8.35M | -7.62M | -1.54M |
| ChangeInWorkingCapital | -781.00K | 1.91M | 1.09M | 273.00K |
| ChangeInOtherCurrentLiabilities | -69.00K | -69.00K | -95.00K | |
| ChangeInOtherCurrentAssets | -675.00K | 93.00K | 125.00K | |
| ChangeInPayablesAndAccruedExpense | -37.00K | 1.89M | 1.06M | 477.00K |
| ChangeInPayable | -37.00K | 1.89M | 1.06M | 477.00K |
| ChangeInAccountPayable | -299.00K | 961.00K | 459.00K | -16.00K |
| ChangeInReceivables | 19.00K | 55.00K | -204.00K | |
| OtherNonCashItems | 323.00K | 473.00K | 41.00K | 791.00K |
| StockBasedCompensation | 557.00K | 1.54M | 1.73M | 4.16M |
| DepreciationAmortizationDepletion | 22.00K | 21.00K | 12.00K | 3.00K |
| DepreciationAndAmortization | 22.00K | 21.00K | 12.00K | 3.00K |
| Depreciation | 22.00K | 21.00K | 12.00K | 3.00K |
| OperatingGainsLosses | -46.00K | -2.19M | -1.17M | -2.72M |
| GainLossOnInvestmentSecurities | -46.00K | -2.19M | -1.17M | -2.73M |
| GainLossOnSaleOfPPE | 0.00 | 0.00 | 8.00K | |
| NetIncomeFromContinuingOperations | -10.21M | -10.11M | -10.49M | -4.04M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for NRSN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|